Chromic Chloride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Chromic Chloride
- Chromic Chloride: From a Parenteral Trace-Element Supplement to Primary Hereditary Glaucoma
Chromic Chloride: From a Parenteral Trace-Element Supplement to Primary Hereditary Glaucoma
One-Sentence Summary
Chromic chloride is a trivalent chromium salt used as a trace-element supplement in parenteral nutrition and is marketed in Singapore as an infusion concentrate. The TxGNN model predicts it may be effective for primary hereditary glaucoma, but this is a computational prediction only. Currently there are 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence data (use as a trace-element supplement in parenteral nutrition) |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 95.70% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, chromic chloride is a trivalent chromium (chromium III) salt given as a trace element in parenteral nutrition. Chromium is thought to play a role in glucose and lipid metabolism, but that role is not established by the data compiled for this report.
No mechanistic link has been established between chromium(III) and glaucoma. No known pathway connects it to trabecular meshwork function, aqueous humour dynamics, intraocular pressure regulation or retinal ganglion cell protection. The high TxGNN score reflects a knowledge-graph pattern and does not constitute biological or clinical validation.
The other top predictions show the same lack of support:
| Rank | Predicted Indication | Score | Evidence |
|---|---|---|---|
| 2 | Open-angle glaucoma | 95.32% | None |
| 3 | Amenorrhea | 93.72% | None (speculative link via insulin sensitivity and PCOS) |
| 4 | Filariasis | 91.47% | None |
| 5 | Trigeminal autonomic cephalalgia | 90.73% | None |
| 6 | Headache disorder | 90.72% | None (likely overlaps with rank 5) |
| 7 | Peripheral arterial disease | 90.51% | None (speculative link via glycaemic and lipid effects) |
| 8 | Congenital hypotrichosis milia | 90.01% | None |
| 9 | Pulmonary hypertension | 89.55% | None |
| 10 | Glaucoma 1, open angle | 89.32% | None (near-duplicate of rank 2) |
Several of these predictions (ranks 1, 2 and 10) are closely related glaucoma entries, so they do not represent independent signals.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15302P | ADDAVEN CONCENTRATE FOR SOLUTION FOR INFUSION | Infusion, solution concentrate | Not listed in the licence data |
This is the only valid registration (single-ingredient product, manufactured by HP Halden Pharma AS). It is an injectable product only, and no formulation for ocular use is registered.
Safety Considerations
- Drug Interactions: 44 interactions were identified in total. All of the 20 shown in the data compiled for this report are rated Moderate. They are mainly with antidiabetic agents, which is consistent with chromium's possible effects on glucose metabolism. Examples:
- Insulin products (insulin human, insulin aspart)
- Biguanides and thiazolidinediones (metformin, pioglitazone)
- Sulfonylureas (chlorpropamide, glimepiride, glipizide, glyburide, acetohexamide)
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
- DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin)
- GLP-1 receptor agonists and alpha-glucosidase inhibitors (albiglutide, dulaglutide, exenatide, acarbose)
Concurrent use may require glucose monitoring.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a knowledge-graph score, with no clinical trials, no publications and no plausible mechanism linking chromium(III) to glaucoma. The product is also an intravenous trace-element supplement, which is not a suitable route for an eye disease. The evidence level is L5.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Singapore-registered product (this is a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Preclinical or mechanistic evidence linking chromium(III) to intraocular pressure regulation or optic nerve protection
- A route and formulation feasibility assessment, since only an intravenous product is currently registered
- A systematic literature search to confirm that no supporting studies exist for any of the top predictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.